معرفی
Dennis C. Sgroi, MD, is Professor of Pathology at Harvard Medical School and Executive Vice-Chair of Pathology at Massachusetts General Hospital (MGH), where he also serves as Director of Breast Pathology. He leads the Sgroi Laboratory within the Molecular Pathology Unit and the Krantz Family Center for Cancer Research at MGH.
Education & Training:
- MD, University of Connecticut School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board certified: Anatomic & General Pathology, American Board of Pathology
Research Focus:
Dr. Sgroi’s laboratory integrates multi-omics technologies to discover and validate molecular biomarkers that predict breast-cancer recurrence and therapeutic response. Core projects include the clinically-adopted Breast Cancer Index (BCI) assay (HOXB13/IL17RB), deciphering HOXB13-mediated tumor-microenvironment remodeling in ER-positive and triple-negative breast cancer, and developing combinatorial therapies targeting HOXB13/ERBB2 co-amplified tumors with BRCA1 loss.
Clinical Impact & Guidelines:
The BCI biomarker has been prospectively validated in multiple randomized trials (NSABP-B-42, Trans-aTTom) and is now incorporated into NCCN and ASCO treatment guidelines for extended adjuvant endocrine therapy in post-menopausal women with ER-positive breast cancer.
Scientific Awards & Honors:
While individual awards are not enumerated in the supplied text, the sustained funding of ~ $19 million in annual direct research costs attests to national peer-review recognition.
Research Team & Collaborations:
The Sgroi Lab includes post-doctoral fellows, graduate researchers, and staff scientists such as Marinko Sremac, PhD. Collaborative networks span Dana-Farber/Harvard Cancer Center Breast Cancer and Cancer Genetics Programs, NRG Oncology, and international genomic consortia.
